Skip to main content
Evidence Snapshot

Serine/threonine-protein kinase Chk1

CHEMBL4630 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4630
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Serine/threonine-protein kinase Chk1 as ChEMBL target CHEMBL4630, mapped to UniProt O14757. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Serine/threonine-protein kinase Chk1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL4630
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O14757
Serine/threonine-protein kinase Chk1
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Serine/threonine-protein kinase Chk1 matters

As of 2026-09-14

Serine/threonine-protein kinase Chk1 is reviewed as Serine/threonine-protein kinase Chk1 (UniProt O14757); Serine/threonine-protein kinase Chk1 shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block.; 6 linked drugs keep this evidence frame grounded.; the current evidence base includes 9 approved drugs, 5713 compounds, and 1059 assays, with lead potency reaching pChEMBL 10.9.

Disease context
neoplasm

Serine/threonine-protein kinase Chk1 shows clinical signal disease relevance led by neoplasm. 5 more disease programs remain visible in the same review block. 6 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include AZD-7762, PF-00477736, PREXASERTIB.

Start review with neoplasm because it currently carries clinical signal support. Linked drugs include AZD-7762, PF-00477736, PREXASERTIB, RABUSERTIB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Clinical signal 6 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 9 approved drugs, 5713 compounds, and 1059 assays for this target. The dominant activity type is IC50. CHEMBL5747621 is the current potency anchor at pChEMBL 10.9.

Use CHEMBL5747621 as the tractability anchor when discussing potency (pChEMBL 10.9).

Activity source · ChEMBL 36 via Core Engine
9 approved pChEMBL 10.9
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Serine/threonine-protein kinase Chk1 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt O14757, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why neoplasm is currently treated as clinical signal support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

5713
Total Compounds
1059
Total Assays
9
Approved Drugs
IC50: 3149.0, KI: 1221.0, EC50: 277.0, KD: 367.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL5747621
 10.9 IC50 —
No preferred name
CHEMBL5812486
 10.8 IC50 —
No preferred name
CHEMBL5944770
 10.8 IC50 —
No preferred name
CHEMBL6027444
 10.8 IC50 —
No preferred name
CHEMBL5935192
 10.7 IC50 —

Approved Drugs

Structure Compound First Approval
BRIGATINIB
CHEMBL3545311
 2017
NINTEDANIB
CHEMBL502835
 2014
SUNITINIB
CHEMBL535
 2006
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-14T03:22:38Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL4630